|
Interferon alfacon-1
resources
|
|
|
|
|
|
DRUG INFO
Interferon alfacon-1
Drug Name:
Interferon alfacon-1
Indication: For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
Pharmacology: Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.
Mechanism Of Action: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
Drug Category: Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents
Brand Names/Synonyms: Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; Infergen (InterMune Inc; Amgen)
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Consensus sequence interferon alpha
Chemical Formula: C860H1353N227O255S9
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00062
CAS Registry Number: 118390-30-0
|
|
|
|
|
|
Interferon alfacon-1 News
(When available)
Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug ... Jan 3, 2006
Finanzen.net, NYSE:VRX) todayannounced that it has completed its acquisition of the United Statesand Canadian rights to the hepatitis C drug Infergen(R) (interferonalfacon-1 ...
Valeant Pharmaceuticals Completes Acquisition of Hep-C Drug ... Jan 3, 2006
Business Wire (press release), NYSE:VRX) today announced that it has completed its acquisition of the United States and Canadian rights to the hepatitis C drug Infergen(R) (interferon alfacon ...
InterMune Completes Divestiture of Infergen(R) for up to $135.5 ... Jan 3, 2006
PR Newswire (press release), ...(Nasdaq: ITMN) announced today the completion of the sale of its United States and Canadian rights to Infergen(R) (interferon alfacon-1), approved for the ...
Valeant buys InterMune hepatitis C drug Jan 3, 2006
San Francisco Business Times, Valeant Pharmaceuticals International said Tuesday it closed its purchase of the United States and Canadian rights to hepatitis C drug Infergen from InterMune ...
(PRN) - SPADE Defense Index Outperforms S&P 500 for Sixth ... Jan 3, 2006
Bolsamania.com, Research Segment Restructuring ... [+. PRN) - InterMune Completes Divestiture of Infergen(R) for up to $135.5 Million in Cash ... [+.
Zacks.com announces that Richard Moroney highlights the following ... Dec 15, 2005
Business Wire (press release), They manufacture and market four human therapeutic products, EPOGEN(R) (Epoetin alfa), NEUPOGEN(R) (Filgrastim), INFERGEN(R) (Interferon alfacon-1) and STEMGEN ...
|
|
|
